PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke
Thavarak Ouk, Camille Potey, Sophie Gautier, Michele Bastide, Dominique Deplanque, Bart Staels, Patrick Duriez, Didier Leys and Regis Bordet
Pages 752-767 (16)
Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous
preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated
in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the
entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches,
acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences.
There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection,
to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences.
This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their
agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors,
acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs
could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology
of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different
phases of ischemia.
Disease-modifying drugs, PPAR, stroke.
Departement de Pharmacologie Medicale, Faculte de Medecine, 1 place de Verdun, F-59045 Lille cedex, France.